Federico Hovera*
Pharmaceutical policies play a crucial role in shaping healthcare systems, ensuring access to affordable and effective medicines, and promoting public health. In an era of limited resources and escalating healthcare costs, decision-makers face the challenge of allocating funds efficiently while maintaining high-quality care. Cost-effectiveness analysis (CEA) has emerged as a valuable tool for assessing the impact of pharmaceutical policies on healthcare decision-making. This article examines the significance of CEA in evaluating the cost-effectiveness of pharmaceutical interventions and its influence on healthcare policy formulation. CEA is a systematic approach that compares the relative costs and outcomes of different healthcare interventions, including pharmaceuticals. It provides decision-makers with evidence on the value of interventions and their efficiency in achieving desired health outcomes. CEA typically measures the cost per unit of health gain, such as cost per Quality-Adjusted Life Year (QALY) gained. By quantifying costs and benefits in a standardized manner, CEA enables policymakers to make informed decisions regarding the allocation of scarce healthcare resources.
Teile diesen Artikel
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi 